Cover Image


Global Diabetic Neuropathy Market 2014-2018

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 302347
出版日期 內容資訊 英文 55 Pages
Back to Top
全球糖尿病神經病變市場 Global Diabetic Neuropathy Market 2014-2018
出版日期: 2014年05月09日 內容資訊: 英文 55 Pages



第1章 摘要整理

第2章 簡稱清單

第3章 調查範圍

  • 市場概要
  • 主要的產品

第4章 市場調查手法

  • 市場調查流程
  • 調查手法

第5章 簡介

第6章 市場形勢

  • 市場概要
  • 市場規模與預測
  • 波特的五力分析

第7章 地區區分

第8章 購買標準

第9章 推動市場成長要素

第10章 推動因素與其影響

第11章 市場課題

第12章 推動因素與課題的影響

第13章 市場趨勢

第14章 趨勢與其影響

第15章 業者情勢

  • 競爭模式
  • 市場佔有率分析
  • 其他卓越供應商

第16章 主要供應商分析

  • 產業概要、產業區分、主要資訊、SWOT分析
    • Pfizer Inc.
    • Eli Lilly and Company
    • Janssen Pharmaceuticals Inc.

第17章 開發平台分析

第18章 相關報告


Product Code: IRTNTR3501

About Diabetic Neuropathy

Diabetes is usually associated with progressive damage to the nervous system, which leads to disorders collectively known as diabetic neuropathy. Diabetic neuropathy is characterized by progressive damage to the neuronal myelin sheath, which slows down nerve conduction velocity. Axonal damage associated with diabetic neuropathy decreases nerve action potential below normal physiological level, which inhibits neuronal signal transmission. About 60 to 70 percent of the diabetic population develops neuropathy, with a considerable number of cases going undiagnosed during the initial years of progression. Disease management should start with the initial diagnosis of diabetes, from educating patients to giving them regular check-ups. Diabetic neuropathy treatment involves bringing blood glucose levels within the normal range to check for further nerve damage and also additional treatment to provide symptomatic relief. Alternative therapies, which help in managing pain, such as biofeedback, meditation, acupuncture or other relaxation techniques can also be used.

TechNavio's analysts forecast the Global Diabetic Neuropathy market will grow at a CAGR of 8.41 percent over the period 2014-2018.

Covered in this Report

This report covers the present scenario and the growth prospects of the Global Diabetic Neuropathy market for the period 2014-2018. To calculate the market size, the report considers revenue generated through the sales of various pain management drugs administered to relieve the pain symptoms associated with diabetic neuropathy. The report also presents the vendor landscape and a corresponding detailed analysis of the top vendors in the Global Diabetic Neuropathy market. In addition, it discusses the major drivers that influence the growth of the market. It also outlines the challenges faced by the vendors and the market at large, as well as the key trends that are emerging in the market.

TechNavio's report, the Global Diabetic Neuropathy Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas and the EMEA and APAC regions; it also covers the Global Diabetic Neuropathy market landscape and its growth prospects in the coming years.

Key Regions

  • Americas
  • EMEA
  • APAC

Key Vendors

  • Eli Lilly and Co.
  • Janssen Pharmaceuticals Inc.
  • Pfizer Inc.

Other Prominent Vendors

  • Actavis plc
  • Cephalon Inc.
  • MEDA Pharma GmbH & Co. KG

Key Market Driver

  • Increasing Global Diabetic Population.

For a full, detailed list, view our report.

Key Market Challenge

  • High Failure Rate in Clinical Trials.

For a full, detailed list, view our report.

Key Market Trend

  • Increasing R&D Activities.

For a full, detailed list, view our report.

Key questions answered in this report:

  • What will the market size be in 2018 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

01. Executive Summary

02. List of Abbreviations

03. Scope of the Report

  • 03.1. Market Overview
  • 03.2. Product Offerings

04. Market Research Methodology

  • 04.1. Market Research Process
  • 04.2. Research Methodology

05. Introduction

06. Market Landscape

  • 06.1. Market Overview
  • 06.2. Market Size and Forecast
  • 06.3. Five Forces Analysis

07. Geographical Segmentation

08. Buying Criteria

09. Market Growth Drivers

10. Drivers and their Impact

11. Market Challenges

12. Impact of Drivers and Challenges

13. Market Trends

14. Trends and their Impact

15. Vendor Landscape

  • 15.1. Competitive Scenario
    • 15.1.1. Key News
    • 15.1.2. Mergers and Acquisitions
  • 15.2. Market Share Analysis 2013
  • 15.3. Other Prominent Vendors

16. Key Vendor Analysis

  • 16.1. Pfizer Inc.
    • 16.1.1. Business Overview
    • 16.1.2. Key Information
    • 16.1.3. SWOT Analysis
  • 16.2. Eli Lilly and Company
    • 16.2.1. Business Overview
    • 16.2.2. Business Segmentation
    • 16.2.3. Key Information
    • 16.2.4. SWOT Analysis
  • 16.3. Janssen Pharmaceuticals Inc.
    • 16.3.1. Business Overview
    • 16.3.2. Key Information
    • 16.3.3. SWOT Analysis
    • 17. Pipeline Analysis
  • 17.1. Phase III Analysis
  • 17.2. Phase II Analysis
  • 17.3. Phase I Analysis
  • 17.4. Discontinued Projects
  • 17.5. Projects on Hold
  • 17.6. Promising Pipeline Molecules
    • 17.6.1. Phase III Promising Pipeline Molecules
    • 17.6.2. Phase II Promising Pipeline Molecules
  • 17.7. Other First-in-class Pipeline Molecules:

18. Other Reports in this Series

List of Exhibits:

  • Exhibit 1: Market Research Methodology
  • Exhibit 2: Global Diabetic Neuropathy Market 2013-2018 (US$ billion)
  • Exhibit 3: Global Diabetic Neuropathy Market by Geographical Segmentation 2013
  • Exhibit 4: Eli Lilly and Company: Business Segmentation
  • Exhibit 5: Diabetic Neuropathy Pipeline Snapshot 2013
  • Exhibit 6: Discontinued Pipeline Molecules on the basis of MOA
Back to Top